PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while TRAW shows 61301.60% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-105.80%
Operating expenses reduction while TRAW shows 75603.42% growth. Joel Greenblatt would examine advantage.
-105.80%
Both companies reducing total costs. Martin Whitman would check industry trends.
-50.00%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
94.20%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
94.20%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while TRAW shows 1151.26% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-94.81%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
94.81%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
98.22%
EPS growth while TRAW declines. John Neff would investigate advantages.
98.22%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
200.00%
Share count reduction below 50% of TRAW's 129.98%. Michael Burry would check for concerns.
200.00%
Diluted share reduction below 50% of TRAW's 129.98%. Michael Burry would check for concerns.